Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SAs allogenic CAR-T therapies. Preliminary results from two trials in CD19+ relapsed or refractory B-Cell acute lymphoblastic leukemia patients dosed with UCART19 suggest that cytokine release syndrome (CRS) associated with allogenic CAR-Ts must be managed very carefully.
Dutch venture capital company BioGeneration Ventures (BGV) has closed its third fund, BGV III, at €82m exceeding the original target by €32m.
Belgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq totalling US$200m plus a fully exercised greenshoe option amounting aggregate gross proceeds to US$230.
The worlds largest event for pharma professionals, CPHI worldwide, will see an expansion to the rapidly-growing field of biologics next year in Madrid
US biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (€85m) expansion plan for the company’s campus there.
Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition.
Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EUs climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.